![](https://library.celltelligence.com/wp-content/uploads/2023/07/Screenshot-2023-07-28-at-16.43.49.png)
$0
Precision Receives Feedback from the FDA on Azer-cel’s Registrational Pathway
On Thursday, July 27, Precision Biosciences announced (press release) the receipt of final Type B meeting minutes from the FDA providing clarity on the potential registrational pathway of its lead asset azer-cel (PBCAR0191; allogeneic CD19 CAR-T). Moreover, the company disclosed discussions with multiple potential strategic partners for the development of its cell therapy assets. Below, Celltelligence provides insights on azer-cel’s potential in LBCL, while comparing the asset with its main allogeneic competitors.